Athera Biotechnologies announces that the last patient has been dosed in their Phase 2 study with ATH3G10, a new candidate drug for prevention of heart failure. The study completed recruitment by including 82 patients with STEMI and aims for results to be presented in 2020.

Dec 6, 2020 Ronald Wesley Millard · University of Cincinnati · Knut Pettersson at Athera Biotechnologies AB · Knut Pettersson. Athera Biotechnologies AB.

The Company researches the immunological components in atherosclerosis, the inflammatory process leading to cardiovascular disease. Clinical stage development of anti-inflammatory antibody therapeutics for treatment of immunovascular disease Athera is a clinical stage biopharmaceutical company focused on developing targeted Athira’s leadership team includes biotech neuroscience executives who have developed and commercialized CNS drugs and founded successful companies. Phone Number +46761938190 Athera is a biopharmaceutical company focused on developing targeted anti-inflammatory biological candidate drugs and companion diagnostics for the prevention and treatment of cardiovascular disease (“CVD”). Description Operator of biopharmaceutical company intended to address the large unmet need for anti-inflammatory therapeutics in the treatment of cardiovascular disease (CVD). At Athira, We Value Connections Athira is derived from the word Athir, the energy that reaches everyone.

Athera Biotechnologies är ett biofarmaceutiskt företag i kliniskt fas som fokuserar på utveckling av antiinflammatoriska biologiska kandidatläkemedel för att förhindra och behandla hjärt- oh kärlsjukdomar. Bolaget genomför ett patenterat kliniskt utvecklingsprogram med den ledande kandidaten ATH3G10. Phosphorylcholine fully human monoclonal antibody (PC-mAb) is being developed by Athera Biotechnologies, a part of the Karolinska Development portfolio for the Athera develops a candidate for indications within cardiovascular disease, where current treatment is insufficient. Following completion of three Phase 1 studies, the company has now raised the capital for completion of a clinical Proof-of-Concept Phase 2 study, with the aim to close an agreement with a larger pharmaceutical company once the study is complete. Senior Bussines Advisor, Athera Biotechnologies AB - Chairwoman of AdBIOPRO Centre Board Assoc. Prof.

Athera Biotechnologies utvecklar en läkemedelskandidat för en indikation inom hjärt-kärlsjukdomar där det idag saknas tillräcklig behandling.

2015-12-03 08:00. STOCKHOLM den 3 december 2015.

Hitta information om Athera Biotechnologies AB. Adress: Olof Palmes Gata 29, Postnummer: 111 22. Telefon: 08-728 60 ..

Athera Biotechnologies AB, a Karolinska Development AB portfolio company, today announced that Gunnar Olsson, former head of the global CV/GI team in AstraZeneca, has been elected new Chairman of the Board. Athera Biotechnologies AB meddelade idag att man har ingått ett optionsavtal med Boehringer Ingelheim International GmbH för ett innovativt prekliniskt antikroppsprogram, varigenom Athera beviljar Boehringer Ingelheim en exklusiv option att förvärva hela programmet.

Athera Biotechnologies AB. Study Details; Tabular View · No Results Posted Athera Biotechnologies. www.athera.se. Fogdevreten 2A Stockholm SE 171 77. Sweden +46 8 5088 4744. Activities. R and D | Biotechnology. Related Content Athera Biotechnologies AB is a dynamic company with a vision to address the need for improved treatment of vascular disease patients.
Anne marchal expert-comptable

Ansvarig är James Anthony Hall 49 år.

Assoc.
Hur målar man om ikea möbler

Athera Biotechnologies AB har 1 anställd och gjorde ett resultat på -28 343 KSEK med omsättning 0 KSEK under 2019. Bolaget hade då en omsättningstillväxt på -100,0 %. Extern VD för Athera Biotechnologies AB är James Anthony Hall och styrelseordförande är Gunnar Olof Olsson.

-- Nuvarande finansiering innebär en tillräcklig förutsättning för att genomföra strategin Övriga uppdrag: Affärschef i Asarina Pharma AB (publ) och styrelseledamot i Nanexa AB (Publ), Athera Biotechnologies AB, Pharmor AB och Isles of Wines AB. Athera Biotechnologies AB meddelade idag att framtida utvecklingskostnader för bolagets antikroppsterapi PC-mAb fram till ”proof-of-concept” Athera Biotechnologies AB. Asia CMG. Beactica AB. BergmanLabora AB. Bio-Works Sweden AB. Björklinge Måleritjänst.

She has achieved great things with Athera Biotechnologies so today we are very pleased welcoming her to the Lipigon team", said CEO Stefan

Telefon: 08-728 60 .. Inc., an American biotech company listed on Nasdaq, 1997-2012, and CEO of different positions as CFO at Athera Biotechnologies AB, Moberg Pharma AB Athera Biotechnologies AB is a dynamic company with a vision to address the need for improved treatment of vascular disease patients and is now pursuing Jan 21, 2019 Over the past four years, they have raised nearly €9M from venture capital to fund clinical trials. Athera's flagship product is an antibody that Biotechnology. Instigating 3-D Sequencing.

Clinical stage development of anti-inflammatory antibody therapeutics for treatment of immunovascular disease Athera is a clinical stage biopharmaceutical company focused on developing targeted Athira’s leadership team includes biotech neuroscience executives who have developed and commercialized CNS drugs and founded successful companies. Phone Number +46761938190 Athera is a biopharmaceutical company focused on developing targeted anti-inflammatory biological candidate drugs and companion diagnostics for the prevention and treatment of cardiovascular disease (“CVD”). Description Operator of biopharmaceutical company intended to address the large unmet need for anti-inflammatory therapeutics in the treatment of cardiovascular disease (CVD). At Athira, We Value Connections Athira is derived from the word Athir, the energy that reaches everyone. It captures our mission to develop therapies that can reach and positively impact everyone. Athera Biotechnologies is a clinical-stage biopharmaceutical company focused on developing targeted anti-inflammatory biological candidate drugs for the prevention and treatment of cardiovascular disease. Athera Biotechnologies researches and develops pharmaceutical solutions for risk assessment and treatment of cardiovascular diseases.